Melissa Beelen
Plus aucun poste en cours
Profil
Melissa Beelen worked as a Senior Director & Head-Clinical Operations at Epizyme, Inc. from 2015 to 2019.
Prior to that, she worked as a Senior Director-Clinical Strategy & Delivery at IQVIA Holdings, Inc. from 2010 to 2015 and as a Manager-Clinical Program at GSK Plc from 1998 to 2010.
She also worked as an Associate at ClinTrials Research, Inc. from 1994 to 1996.
Ms. Beelen holds an undergraduate degree from North Carolina State University and the University of North Carolina System.
Anciens postes connus de Melissa Beelen
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | 01/03/2019 |
| IQVIA HOLDINGS INC. | Corporate Officer/Principal | 01/11/2015 |
| GSK PLC | Corporate Officer/Principal | 01/01/2010 |
ClinTrials Research, Inc.
 ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The private company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Corporate Officer/Principal | 01/01/1996 |
| IN8BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Melissa Beelen
| North Carolina State University | Undergraduate Degree |
| University of North Carolina System | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GSK PLC | Health Technology |
| IQVIA HOLDINGS INC. | Health Services |
| IN8BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ClinTrials Research, Inc.
ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The private company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Commercial Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
